Skip to main content
Erschienen in: Neuroradiology 6/2020

20.02.2020 | Diagnostic Neuroradiology

Atypical radiological findings of primary central nervous system lymphoma

verfasst von: Xuling Lin, Iram Rais Alam Khan, Ying Hao Christopher Seet, Hwei Yee Lee, Wai-Yung Yu

Erschienen in: Neuroradiology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Primary central nervous system lymphoma (PCNSL) presenting with atypical radiological findings often leads to delayed diagnosis. We aim to characterize the radiological features and apparent diffusion coefficient (ADC) values of PCNSL with atypical neuroimaging presentation in our local population.

Methods

We retrospectively reviewed all patients with histological diagnosis of CNS lymphoma at our tertiary center from 2005 to 2016. We screened all initial pre-treatment MRIs and excluded cases with typical imaging findings of contrast-enhancing lesions without intra-lesional susceptibility and central non-enhancement. Additional exclusion criteria included (i) relapsed PCNSL, (ii) secondary CNS lymphoma, and (iii) positive HIV status. Two independent raters scored MRI and CT scans at presentation. We computed ADC values in the tumors by 2 methods: single region of interest (ROI1) and multiple ROI (ROI2).

Results

Sixteen (25.4%) of 63 patients with CNS lymphoma met inclusion criteria. There were 8 men; median age was 61 (range 22–81) years. Histological diagnoses were diffuse large B cell lymphoma (n = 14) and intravascular lymphoma (n = 2). Fifteen (93%) patients had enhancing lesions (5 solitary; 10 multifocal); most enhancing lesions had T1 hypointense (67%) and T2 mixed (53%) signals, and 6 (40%) had central non-enhancing regions. Nine (56%) patients had lesions with susceptibility. Using the ROI methods, median values for minimum ADC and mean ADC ranged 0.65–0.71 × 10–3 mm2/s and 0.79–0.84 × 10–3 mm2/s respectively.

Conclusion

PCNSL with atypical radiological features represented one-fourth of our histologically diagnosed lymphoma cases; low ADC values in atypical lesions should prompt clinicians to consider early biopsy for definitive diagnosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
7.
Zurück zum Zitat Lin X, Lee M, Buck O, Woo KM, Zhang Z, Hatzoglou V, Omuro A, Arevalo-Perez J, Thomas AA, Huse J, Peck K, Holodny AI, Young RJ (2017) Diagnostic accuracy of T1-weighted dynamic contrast-enhanced-MRI and DWI-ADC for differentiation of glioblastoma and primary CNS lymphoma. AJNR Am J Neuroradiol 38(3):485–491. https://doi.org/10.3174/ajnr.A5023 CrossRefPubMed Lin X, Lee M, Buck O, Woo KM, Zhang Z, Hatzoglou V, Omuro A, Arevalo-Perez J, Thomas AA, Huse J, Peck K, Holodny AI, Young RJ (2017) Diagnostic accuracy of T1-weighted dynamic contrast-enhanced-MRI and DWI-ADC for differentiation of glioblastoma and primary CNS lymphoma. AJNR Am J Neuroradiol 38(3):485–491. https://​doi.​org/​10.​3174/​ajnr.​A5023 CrossRefPubMed
8.
Zurück zum Zitat Maeda M, Kato H, Sakuma H, Maier SE, Takeda K (2005) Usefulness of the apparent diffusion coefficient in line scan diffusion-weighted imaging for distinguishing between squamous cell carcinomas and malignant lymphomas of the head and neck. AJNR Am J Neuroradiol 26(5):1186–1192PubMed Maeda M, Kato H, Sakuma H, Maier SE, Takeda K (2005) Usefulness of the apparent diffusion coefficient in line scan diffusion-weighted imaging for distinguishing between squamous cell carcinomas and malignant lymphomas of the head and neck. AJNR Am J Neuroradiol 26(5):1186–1192PubMed
Metadaten
Titel
Atypical radiological findings of primary central nervous system lymphoma
verfasst von
Xuling Lin
Iram Rais Alam Khan
Ying Hao Christopher Seet
Hwei Yee Lee
Wai-Yung Yu
Publikationsdatum
20.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Neuroradiology / Ausgabe 6/2020
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI
https://doi.org/10.1007/s00234-020-02377-0

Weitere Artikel der Ausgabe 6/2020

Neuroradiology 6/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.